By Fineline Cube 
Shanghai-based genome medicines specialist HuidaGene Therapeutics has sublicensed its hfCas12Max platform to Vita Therapeutics, Inc., through Synthego Corporation, marking a significant expansion into new therapeutic territories. The agreement allows Vita to utilize HuidaGene’s high-fidelity CRISPR-Cas12 technology in developing cell therapies for neuromuscular disorders.
Collaboration Details
Under the terms of the agreement, Vita Therapeutics gains the right to use HuidaGene’s engineered hfCas12Max nuclease and optimized guide RNAs in preclinical and clinical settings. This includes the development of hypoimmunogenic induced pluripotent stem cell (iPSC)-based cell therapies targeting neuromuscular disorders, leveraging the precision and efficiency of the hfCas12Max platform.
Technology Platform
HuidaGene’s hfCas12Max platform, developed through its proprietary AI-powered HG-PRECISE™ platform, was initially licensed to Synthego in May 2024 for manufacturing, commercialization, and sublicensing. This platform is recognized for its high fidelity and efficiency in gene editing, making it an ideal choice for advancing innovative cell therapies.
Market and Therapeutic Potential
The collaboration positions both companies at the forefront of genetic medicine innovation, addressing significant unmet needs in neuromuscular disorders. By combining HuidaGene’s advanced CRISPR technology with Vita’s expertise in cell therapy development, the partnership aims to deliver transformative treatments for patients.-Fineline Info & Tech